AUGUSTA, Maine — Maine stands to get about $43,000 as part of a $34 million settlement that the maker of an epilepsy treatment drug has agreed to pay for marketing the drug in violation of U.S. drug laws.
The U.S. subsidiary of Belgian manufacturer UCB pleaded guilty Thursday in federal court in Washington to a misdemeanor in connection with the misbranding. The company will pay a criminal fine of more than $7 million, forfeit $1 million in assets and pay nearly $26 million to resolve civil claims that it promoted off-label uses of the drug, including for migraines, pain, mood disorders and anxiety.
As part of the civil settlement, nearly $10 million will go to Medicaid programs in Maine and other states.
Maine Attorney General William Schneider said UCB put “profit ahead of patients.”